Saturday, July 25, 2009 8:52 AM
From:
"Suncica Bulat Wuersching" bulat@kuca-zdravlja.com
To:
Rotarian Cancer Support Group
emattson0711@yahoo.com
Dear Rotarian friend Mattson,
I will take the liberty to address you and ask for you assistance. Namely, I am past president of RC Zagreb Croatia, RID 1910 and my Dad is past president of RC Zagreb and assistant governor in our District. My Dad's wife was diagnosed with metastatic melanoma 4 months ago. I am a medical doctor myself and it is terrible to watch them struggle. We've been in touch with Dr Chapman in Sloan-Kettering Memorial Hospital in NY to seek help for Verica, born 1957 (42 years old), to receive an experimental treatment for melanoma. We've faxed all relevant findings and she was supposed to be included in the study. Although she fulfills all the criteria, suddenly they said she should live in USA for one year.
Since my Dad is a CEO of his own company, it is difficult for them to leave for so long. Otherwise, coming for regular treatment and check-ups is not a problem. I hope I haven't burdained you with our request for your kind assistance. But since it is a matter of survival, I will be so free to beg of you to try getting Verica in the study conducted in Sloan-Kettering Memorian if possible. Thank you very much for your attention. I remain, sincerely, yours in Rotary,
Suncica Bulat Wuersching, PP, PHF, RC Zagreb Centar.
Sent via BlackBerry from Vodafone
Response:
Dear Suncica,
I received your e-mail Saturday morning. I have a couple of very good contacts at MSLCC and will be glad to make a call on Monday to see what we can get accomplished.
I have a couple of questions for you regarding the clinical study....There are six clinical trials for melanoma listed in NIH database. I am familar with all three which utilize immunogical concepts, but I need to know which one is the one you are trying to enroll Verica? :
- Phase 1 clinical study investigating PLX4032 (R7204). PLX4032 is a novel, oral and highly selective drug that targets the BRAFV600E cancer-causing mutation that occurs in most melanomas.
- Clinical study of MOAB 3F8 with I-131 as the toxin in an immunologic setting
- Clinical study of antibody responses with a KLH conjugated bivalent vaccine containing GD2 Lactone, GD3 Lactone with immunological adjuvant QS-DG or OPT-821
Who was the original contact person at MSKCC.
Ed Mattson
Board Chair, Cancer Support Group
Member, Romanian Association of Preventive Oncology
No comments:
Post a Comment